TSM74
Pre-clinical- Indications
- Multiple myeloma, Glioblastoma, Liver cancer, Lung cancer, Bladder cancer, Prostate cancer
Company intelligence / Profile preview
Telo Therapeutics
California, United Statestelotherapeutics.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Telo Therapeutics has generated durable complete responses with just two weeks of dosing in xenografts of both multiple myeloma and glioblastoma[3]. The company is developing orally bioavailable next generation inhibitors of nuclear transport that have shown rapid tumor regressions across multiple cancer types[3].
- Therapeutic areas
- Oncology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Multiple Myeloma Research Foundation (MMRF)[3]
Beyond the preview
Go deeper on Telo Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Telo Therapeutics.